Takeda thins the cell therapy pipeline
The end of three licensed assets sees Takeda take a step back from autologous cell therapy.
Takeda taps Protagonist before it’s Verified
Rusfertide’s big readout will now not come until 2025.
Roche perseveres with FAP
A third discontinuation leaves one anti-FAP project in Roche’s clinical pipeline.
Novartis calls time on TIM-3 and HIF2α
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
Bayer and Lilly make radioligand progress
First-in-human trial initiations feature anti-PSMA radioligands, KRAS G12D, Nectin-4 and more.
Pfizer shuffles its deck post-Seagen
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.
Kura leaves some combo questions unanswered
Komet-007 showed no differentiation syndrome, but the group didn’t disclose data on menin inhibitor-experienced patients.
Gilead doubles down on Arcus
Will a TIGIT refocus see the stars finally align for the partners?
